Inhibitors of microtubule polymerization arrest most cells in a prometaphase-like stage, indicating that a checkpoint monitors chromosome alignment and/or the status of the spindle and regulates the metaphase to anaphase transition. This safeguard helps to ensure accurate transmission of genetic information to the daughter cells. Defects in cell cycle checkpoints increase the frequency of chromosome loss and gene amplification and may play a role in tumor progression ([@B26]; [@B25]; [@B51], [@B52]).

In the budding yeast *Saccharomyces cerevisiae*, spindle disruption arrest depends on the products of three *MAD* (mitotic arrest defective) genes ([@B23]; [@B24]; [@B43]), three *BUB* (budding uninhibited by benzimidazole) genes ([@B28]; [@B64]), and MPS1 (multipolar spindle; [@B40]; [@B72]). Vertebrate homologs of one of these genes, *MAD2*, have recently been identified and found to be important for the spindle assembly checkpoint, indicating that the mechanisms underlying this checkpoint are likely to be well conserved evolutionarily ([@B5]; [@B44]).

In a wide variety of organisms, phosphoprotein dephosphorylation is essential for progression from metaphase to anaphase. Certain fission yeast and *Drosophila* mutants with altered phosphatase activity exhibit metaphase arrest phenotypes ([@B37]; [@B47]; [@B55]). Studies with phosphoepitopespecific antibodies have also implicated dephosphorylation in progression to anaphase ([@B2]; [@B15]; [@B54]). Inactivation of phosphatases that are necessary for anaphase, or activation of kinases that oppose progression into anaphase, could be the mechanism through which defective spindles and misaligned chromosomes bring about mitotic arrest.

[@B48] implicated the Erk2 or p42 mitogen-activated protein kinase (MAP kinase)^1^ protein in the spindle assembly checkpoint through studies of cytoplasmic extracts of *Xenopus* eggs, a system that offers great biochemical manipulability. Previous work had shown that even though *Xenopus* eggs and early embryos lack the DNA synthesis checkpoint---DNA synthesis inhibitors do not affect blastomere cleavage---this checkpoint can be reconstituted by the addition of sperm nuclei to a concentration of ∼250 per μl (higher than the concentration of nuclei in an early embryo, but lower than the concentration of ∼250,000 nuclei per μl for a 4 pl somatic cell; [@B7]). [@B48] examined whether the spindle assembly checkpoint could also be reconstituted by addition of sperm nuclei to the extracts. They found that it could: extracts supplemented with ∼9,000 nuclei per μl arrested in a mitotic state in the presence of nocodazole, and destruction of cyclins B1 and B2 (but not cyclin A1) was suppressed. They also noted that p42 MAP kinase underwent sustained activation in the nocodazoletreated, arrested extracts. Addition of a MAP kinase phosphatase (mouse Mkp-1) that can dephosphorylate and inactivate p42 (Erk2), p44 (Erk1), and p38 (Hog1) MAP kinases, but is minimally active towards other phosphoproteins ([@B1]; [@B19]; [@B36]; [@B67]), resulted in inactivation of the p42 MAP kinase, destruction of cyclins B1 and B2, and release of the extracts from mitotic arrest. These studies showed that MAP kinase, or some closely related protein, is essential for the spindle assembly checkpoint in this reconstituted in vitro system.

Although MAP kinases are probably best known for their transient activation when quiescent cells are prompted to reenter the cell cycle, they are also activated during meiotic maturation in oocytes ([@B12]; [@B20]; [@B35]; [@B60]). MAP kinase activation triggers or facilitates the activation of Cdc2 ([@B18]; [@B22]; [@B30]; Kosako et al., 1994), although the mechanism through which MAP kinase regulates Cdc2 activity remains to be elucidated. Given the similarities between meiotic and mitotic M-phase regulation, these findings raise the possibility that MAP kinase might participate in the activation of Cdc2 at the G2-M transition in somatic cells.

MAP kinase may contribute to M phase in other ways as well. [@B17] observed that MAP kinase is capable of increasing the dynamic instability of microtubules in *Xenopus* egg extracts, which raises the possibility that MAP kinase activity may be necessary for microtubule reorganization at the onset of M phase.

In this study we set out to evaluate the hypotheses that p42 or p44 MAP kinase function is important for entry into mitosis in somatic cells, as suggested by studies of meiotic maturation; for establishing a mitotic spindle, as suggested by studies of microtubule dynamics in cytoplasmic *Xenopus* egg extracts; or for spindle assembly checkpoint control, as suggested by studies of nocodazole-treated, sperm nucleus--supplemented *Xenopus* egg extracts. We chose to carry out our studies in the *Xenopus* tadpole cell line (XTC), both because of the availability of good quality homologous reagents for perturbing MAP kinase function, and because XTC cells remain relatively flat during mitosis, facilitating microscopic examination of mitotic cells. Here we demonstrate that MAP kinase is present in the spindle during specific stages of M phase, consistent with the possibility that MAP kinase regulates the spindle or monitors the status of the spindle. Microinjection of a specific MAP kinase--inactivating enzyme, *Xenopus* MAP kinase phosphatase-1 or XCL100, has no obvious effect on normal mitotic progression but renders cells unable to maintain a mitotically arrested state when mitosis is disrupted by nocodazole treatment. Our results provide in vivo support for the hypothesis that p42 and/or p44 MAP kinase function are required for the spindle assembly checkpoint.

Materials and Methods
=====================

Cell Culture
------------

The *Xenopus* tadpole cell line (XTC) was obtained from Dr. Tim Stearns (Stanford University) and grown at room temperature in 70% L-15 medium supplemented with 10% FBS. Cells to be used for microinjection were plated onto coverslips with photoetched locator grids (Bellco Glass, Inc., Vineland, NJ) and grown for at least 2 d.

Antibodies
----------

The rabbit MAP kinase antiserum X15 was raised against a *Xenopus* p42 MAP kinase COOH-terminal peptide ([@B29]) and affinity purified on a peptide column. Affinity-purified X15 was tested for its specificity by immunoblotting XTC cell lysates. An Erk1 antibody (C-16) was obtained from Santa Cruz Biochemicals (Santa Cruz, CA). MKK-1 antiserum 662, raised against a *Xenopus* MKK-1/Mek-1 NH~2~-terminal peptide, has been described previously ([@B29]). An antibody that recognizes active, but not inactive, Erks 1 and 2 was purchased from Promega (Madison, WI). XCL100 antiserum was raised and provided by M.L. Sohaskey (Stanford University).

Preparation of Cell Lysates
---------------------------

XTC cells were grown to near confluence. Cells were trypsinized and collected by centrifugation. SDS sample buffer was added to the pelleted cells.

Lysates from *Xenopus* oocytes or electrically activated eggs, containing nonphosphorylated p42 MAP kinase, and from progesterone-treated oocytes or nonactivated eggs, containing phosphorylated p42 MAP kinase, were prepared as described ([@B12]; [@B50]).

Immunoblotting
--------------

Oocyte, egg, and XTC cell lysates were separated by SDS 10% polyacrylamide gel electrophoresis, transferred to an Immobilon-P membrane (Millipore Corp., Bedford, MA), and probed with the affinity-purified X15 antibody at 1 μg/ml followed by affinity-purified alkaline phosphatase--conjugated goat anti--rabbit IgG at 1:3,000 (Sigma Chemical Co., St. Louis, MO).

Construction of an XCL100 Expression Plasmid
--------------------------------------------

The wild-type XCL100 cDNA was inserted into pGEX-4T for expression in bacteria as follows: gel-purified 1.6-kb BamHI--XhoI fragment, which contained all but the NH~2~-terminal 130 bp of the XCL100 coding region plus 0.66 kb of the 3′-untranslated region, was ligated into pGEX-4T to yield pGEX-ΔN. The NH~2~-terminal 130-bp fragment was obtained by PCR, with the 5′ primer consisting of a synthetic BamHI site fused to the codon for the initiator methionine and the 3′ primer spanning the natural XCL100 BamHI site. The fidelity of the PCR product was verified by sequencing. The PCR product was digested with BamHI, gel purified, and ligated into the BamHI site of pGEX-ΔN to yield pGEX-XCL100.

A cDNA for the catalytically inactive phosphatase XCL100 C260S, which has a serine residue in place of the essential active site cysteine residue, was generated by PCR by M.L. Sohaskey. An EcoRI--NheI fragment spanning the mutagenized codon was excised and ligated into pGEX-XCL100 to yield pGEX-XCL100 C260S. The protein products of the wild-type and mutant forms of pGEX-XCL100 are fused to the COOH terminus of glutathione-*S*-transferase (GST).

Expression and Purification of XCL100
-------------------------------------

Overnight cultures of *Escherichia coli* transformed with pGEX-XCL100 or pGEX-XCL100 C260S were grown and lysed essentially as described ([@B71]). The clarified cell extracts were recycled over a 2.5-ml column of glutathione agarose (Sigma Chemical Co.) for 5 h at 4°C. The column was washed with 10 vol of PBS, and fusion proteins were eluted with 50 mM Tris, pH 8.0, containing 15 mM glutathione. Fractions were assessed for MAP kinase phosphatase activity, as described below, and peak fractions were pooled. As has been previously reported, XCL100 and XCL100 C260S manifested substantial proteolytic degradation; much of the glutathione agarose--purified protein was digested back to the GST moiety (see Fig. [4](#F4){ref-type="fig"} *A*; see also [@B67]). However, we were able to obtain purified full-length XCL100 or XCL100 C260S proteins by anion exchange chromatography. Peak fractions from the glutathione agarose column were applied to a Mono-Q column (Pharmacia Fine Chemicals, Piscataway, NJ) equilibrated with 20 mM Tris, pH 7.8, 20 mM NaCl, and 2 mM DTT. Proteins were eluted from the column with a linear gradient of 20 mM--1 M NaCl. Activity was recovered in the fractions containing 640--660 mM NaCl, pooled, and dialyzed against the microinjection buffer (130 mM KCl, 10 mM NaPipes, pH 7.0, and 1 mM MgCl~2~ ). Material obtained after the glutathione agarose purification step and after the Mono-Q step exhibited indistinguishable biochemical and biological activities.

We found that the biochemical activity of XCL100 did not survive multiple freeze-thaw cycles or prolonged storage at 4°C. Therefore, for studies described below, we used XCL100 and XCL100 C260S that had been stored at 4°C for no more than 48 h, or, in some experiments, used XCL100 that had been frozen in 10% glycerol, stored at −70°C, and thawed just before its use.

Other Recombinant Proteins
--------------------------

A pRSET-based plasmid for a constitutively active, His~6~-tagged mutant of human MKK-1/Mek-1 (with Ser 218 replaced by Glu, Ser 222 replaced by Asp, and a deletion of amino acids 32--51, hereafter denoted MKK-1\*) was provided by Natalie Ahn (University of Colorado, Boulder). An NheI--HindIII fragment containing the MKK-1\* coding region was subcloned into pFastBac1 for generation of baculoviruses. MKK-1\* was expressed in insect cells and purified to homogeneity by nickel-chelate chromatography by Ramesh Bhatt (Stanford University).

Hexahistidine-tagged, kinase-minus (K52R) rat Erk2 was expressed in *E. coli* and purified by Chi-Ying Huang (Stanford University; [@B30]) from a plasmid provided by Melanie Cobb and Tom Geppert (University of Texas Southwestern Medical Center) ([@B63]). A pT7-7--based plasmid for expression of hexahistidine-tagged *Xenopus* Erk2 was engineered from a *Xenopus* Erk2 cDNA provided by Jonathan Cooper and Jim Posada (Fred Hutchinson Cancer Research Center, Seattle, WA), and it was expressed in *E. coli* and purified by Ramesh Bhatt.

In Vitro Phosphatase Activity Assay
-----------------------------------

To prepare phosphorylated Erk2 for use as a substrate in an XCL100 phosphatase assay, we incubated recombinant kinase-minus rat Erk2 with active MKK-1 that had been obtained from *Xenopus* egg lysates by immunoprecipitation with antibody 662 ([@B29]), and MgATP. The XCL100 phosphatase assay was performed by incubating phosphorylated MAP kinase with purified XCL100 fusion proteins in phosphatase reaction buffer (50 mM Hepes, pH 7.5, 1 mg/ml BSA, 2 mM DTT, and 2 mM EDTA) in a final reaction vol of 60 μl. After incubation for 30 min at 30°C, the reaction was stopped by adding SDS sample buffer, and the sample was boiled. Proteins were separated by SDS 10% polyacrylamide gel electrophoresis and immunoblotted as described above. Dephosphorylation of Erk2 was detected as a shift of the blotted Erk2 band to a lower apparent molecular weight.

MAP Kinase Assay
----------------

MAP kinase activity was assessed by a myelin basic protein phosphorylation assay essentially as described ([@B30]). Reaction mixtures were analyzed by SDS 12.5% polyacrylamide gel electrophoresis, proteins were transferred to an Immobilon P membrane, and incorporation of ^32^P into myelin basic protein was quantified using a phosphorimager (Molecular Dynamics, Sunnyvale, CA).

Microinjection and Nocodazole Treatment
---------------------------------------

Micropipettes were pulled on a horizontal pipette puller (Sutter Instrument Co., Novato, CA). Proteins were microinjected with a Narishiga manual microinjector (Greenvale, NY). The needle concentration of XCL100 protein (both wild-type and mutant forms) was 1.5 μM, and MKK1\* was 10 μM when MKK-1\* was injected alone, and 5 μM when MKK-1\* was coinjected with XCL100.

For checkpoint control experiments, we first microinjected the appropriate protein(s), and then aspirated the medium and added fresh F-15 medium containing nocodazole at 50 ng/ml. Cells were viewed with a ×40 phase-contrast objective (NA 0.75) on an inverted microscope (Carl Zeiss, Inc., Thornwood, NY) equipped with a CCD camera and recorded with an optical disk recorder (Panasonic, Secaucus, NJ) for up to 4 h after injection or treatment with the drug.

Immunofluorescence
------------------

XTC cells were grown on coverslips, fixed with methanol (−20°C) for 6 min, and then treated with a microtubule stabilizing buffer (25 mM imidazole, pH 7.0, 10 mM KCl, 1 mM MgSO~4~, 10 mM EGTA, and 20% glycerol) containing 0.1% Triton X-100 (Pierce Chemical Co., Rockford, IL), followed by washing with PBS. XTC cells were blocked in 3% milk, and then stained with affinity-purified X15 at 8 μg/ml followed by affinitypurified FITC-conjugated goat anti--rabbit IgG at 1:100 (Kirkegaard & Perry Laboratories Inc., Gaithersburg, MD). For triple labeling, the cells were incubated sequentially with X15 and then mouse monoclonal anti-- β-tubulin antibody (Amersham Corp., Arlington Heights, IL) at 1:100. FITC-conjugated anti--rabbit IgG (1:100) and affinity-purified Texas red-- conjugated goat anti--mouse IgG (1:200; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) were mixed and applied. Finally, chromosomes were stained with 4′,6-diamidino-2-phenylindole (DAPI) at 1 μg/ ml for 30 s. Each step was followed by four 10-min rinses with PBS.

Images were obtained using either a ×100, 1.3 NA objective on a Zeiss microscope equipped with a cooled CCD camera or a ×40, 0.9 NA objective on a Zeiss microscope equipped with a conventional 35-mm camera.

Results
=======

Erk2/p42 MAP Kinase Localizes at the Mitotic Spindle after Nuclear Envelope Breakdown and Leaves the Spindle before Anaphase
----------------------------------------------------------------------------------------------------------------------------

The localization of some cell cycle regulators provides a clue to their function. Accordingly, we examined the localization of MAP kinase during M phase in a tissue-culture cell line, XTC. We determined the most suitable of several antisera for immunolocalization studies to be X15, an antipeptide antiserum raised against a *Xenopus* Erk2 (p42) MAP kinase COOH-terminal peptide ([@B29]). X15 recognizes active and inactive forms of *Xenopus* Erk2 equally well, both in immunoprecipitations (nondenaturing conditions) and in immunoblots (denaturing conditions; [@B29]; Fig. [1](#F1){ref-type="fig"}).

We affinity purified X15 antibody on a peptide column and characterized the affinity-purified X15 for its specificity in total XTC lysates. Affinity-purified X15 recognized two bands on immunoblots (Fig. [1](#F1){ref-type="fig"}), corresponding to *Xenopus* Erk1 and Erk2.

We then carried out immunofluorescence studies of XTC cells using affinity purified X15. Fig. [2](#F2){ref-type="fig"} shows the results of triple label staining with X15 (fluorescein staining), antitubulin antiserum (Texas red), and DAPI for DNA staining. In interphase, MAP kinase was diffusely distributed through the cytoplasm (Fig. [2](#F2){ref-type="fig"} *A*). There was no obvious concentration of MAP kinase in the interphase microtubules.

When cells entered prometaphase, much of the MAP kinase staining remained diffusely cytoplasmic, but some of the staining became concentrated on the spindle (Fig. [2](#F2){ref-type="fig"} *B*). MAP kinase was detectable on the spindle during early prometaphase just after nuclear envelope breakdown, and the staining increased during metaphase (Fig. [2](#F2){ref-type="fig"}, *B--C*). During anaphase, the intensity of the MAP kinase staining of the spindle decreased to about the level of intensity of general cytoplasmic staining (Fig. [2](#F2){ref-type="fig"} *D*). Thus, the spindlelike "fingers" of MAP kinase staining seen in Fig. [2](#F2){ref-type="fig"} *D* could include some spindle-associated MAP kinase, but could also simply represent fingers of cytoplasm between MAP kinase--free masses of chromosomes. By late anaphase, the intensity of MAP kinase staining around the spindle was lower than that in other regions of the cell (Fig. [2](#F2){ref-type="fig"} *E*). MAP kinase was not detectable in the midbody, the prominent microtubule-containing structure that forms between the two daughter cells during cytokinesis (Fig. [2](#F2){ref-type="fig"} *F*). Thus, MAP kinase was found to be associated with the spindle during prometaphase and metaphase and to dissociate from the spindle and midbody, or to become inaccessible to antibody staining during anaphase and cytokinesis.

Preimmune serum yielded no spindle staining (Fig. [2](#F2){ref-type="fig"} *G*), indicating that the spindle staining observed with affinitypurified X15 was specific. Preincubation of X15 with the peptide against which it was raised markedly decreased the intensity of both spindle and cytoplasmic staining (Fig. [3](#F3){ref-type="fig"}). Finally, single label immunofluorescence studies with affinity-purified X15 showed spindle staining, confirming that the results seen in the triple label studies were not due to cross-reactivity between secondary antibodies or leakage between the fluorescein and Texas red filters (Fig. [3](#F3){ref-type="fig"}).

These findings demonstrate that Erk1 or Erk2 is present in the spindle during specific subphases of mitosis. This places MAP kinase in an appropriate position to be involved in either regulating the spindle or relaying information about the status of the spindle.

Purified Bacterially Expressed GST-XCL100 Dephosphorylates Erk2 MAP Kinase In Vitro
-----------------------------------------------------------------------------------

We set out to determine whether, in intact XTC cells, MAP kinase activation might be necessary to trigger or maintain Cdc2 activation, as appears to be the case during meiotic maturation ([@B18]; [@B22]; [@B30]; [@B39]); MAP kinase might be needed to maintain the dynamic properties of the M-phase microtubules, as suggested by studies of interphase *Xenopus* egg extracts ([@B17]); or MAP kinase activity might be required for the spindle assembly checkpoint, as suggested by studies of nocodazole-treated, nucleus-supplemented cycling *Xenopus* egg extracts ([@B48]). The approach chosen was to microinject a *Xenopus* MAP kinase phosphatase, XCL100, which could prevent or reverse MAP kinase activation, and determine the consequences by time-lapse video microscopy. XCL100 and its homologs CL100 (human) and Mkp-1 (mouse) are dual-specificity phosphatases that dephosphorylate the phosphothreonine and phosphotyrosine regulatory sites of MAP kinase, thereby inactivating MAP kinase ([@B1]; [@B42]; [@B67]). CL100/Mkp-1 proteins are highly specific for the p42 Erk2, p44 Erk1, and p38 Hog1 MAP kinases in vitro ([@B1]; [@B19]; [@B36]; [@B67]). Transient expression of Mkp-1 in COS cells leads to selective dephosphorylation of MAP kinase from the spectrum of phosphotyrosine-containing proteins ([@B67]), indicating that XCL100/Mkp-1 proteins are highly specific in vivo as well.

We expressed wild-type XCL100 and an engineered catalytically inactive version of XCL100, with Cys 260 mutagenized to Ser (XCL100 C260S), as GST fusion proteins in bacteria. The proteins were purified to homogeneity by glutathione affinity chromatography and Mono-Q anion exchange chromatography (Fig. [4](#F4){ref-type="fig"} *A*). The purified wildtype XCL100 protein potently dephosphorylated p42 MAP kinase (Fig. [4](#F4){ref-type="fig"} *B*) but not Mos, Mek, or Rsk (Huang, C.Y.-F., unpublished data), other enzymes in the MAP kinase pathway. The mutant XCL100 C260S protein did not dephosphorylate MAP kinase (Fig. [4](#F4){ref-type="fig"} *B*).

We then carried out in vitro studies to determine whether it was likely that we could achieve a high enough concentration of XCL100 by microinjection to interfere with Erk1 and Erk2 activation. By microinjection, we should be able to increase the cell\'s XCL100 concentration by ∼75 nM (assuming we can inject 50 fl into a 1 pl cell, and given that the needle concentration of XCL100 was 1.5 μM). The abundance of MKK-1 and Erk1/2 in several cell lines has been estimated to be on the order of 1 μM ([@B11]). In *Xenopus* oocyte extracts, activation of ∼25% of the MKK-1 results in activation of ∼50% of the Erk2 ([@B31]). We added various dilutions of XCL100 to a mixture of recombinant *Xenopus* Erk2 (1 μM) and MKK-1\* (250 nM), in the presence of MgATP, and let the system reach steady state. We found that 38 nM XCL100 was sufficient to half-maximally inhibit Erk2 activation, 75 nM XCL100 inhibited Erk2 activation by 87%, and 150 nM XCL100 inhibited Erk2 activation completely (Fig. [4](#F4){ref-type="fig"} *C*). Based on these in vitro titrations, it appears reasonable to expect XCL100 microinjection to have an effect on MAP kinase activation in vivo, provided the microinjected phosphatase is not rapidly degraded or inactivated.

Microinjection of MAP Kinase Phosphatase Does Not Affect Mitotic Progression
----------------------------------------------------------------------------

To test whether interfering with MAP kinase activation by XCL100 microinjection would affect the mitotic progression, we microinjected XTC cells at different stages of mitosis--- prophase, prometaphase, metaphase, and anaphase---with purified XCL100 protein, and then followed the injected cells by time-lapse video microscopy. We found that 20 out of 20 cells injected with XCL100 (needle concentration 1.5 μM, estimated intracellular concentration 75 nM) progressed to metaphase, initiated anaphase, and cleaved, all with normal kinetics (Table [I](#TI){ref-type="table"}). These findings indicate that either a high level of MAP kinase activity is not required for normal mitotic progression, or the intracellular concentration of XCL100 achieved by microinjection was not sufficient to substantially interfere with MAP kinase activation. The fact that some of the same preparations of XCL100 were found to interfere with checkpoint control, as described below, argues for the first possibility.

Microinjection of MAP Kinase Phosphatase Causes Mitotically Arrested Cells to Exit Mitosis without Sister Chromatid Segregation, Karyokinesis, or Cytokinesis
-------------------------------------------------------------------------------------------------------------------------------------------------------------

Next, we tested the hypothesis that MAP kinase function is required for the spindle assembly checkpoint, as suggested by experiments in nucleus-supplemented *Xenopus* egg extracts ([@B48]). Treatment of noninjected, mitotic XTC cells with nocodazole (0.05 μg/ml) resulted in rapid disappearance of the spindle (generally within 3 min), including the kinetochore microtubules (data not shown). Cells then remained blocked in a pseudo-prometaphase stage with scattered chromosomes for up to 12 h.

Our initial approach to determining whether XCL100 microinjection might interfere with this arrest was to arrest XTC cells in a pseudo-prometaphase stage by treatment with nocodazole, then inject XCL100 protein, and finally follow the cells to see whether they would exit mitosis. However, the nocodazole-treated XTC cells proved too fragile to microinject; they often swelled and died (as indicated by cessation of cytoplasmic streaming) immediately after injection.

Therefore, we chose to identify and microinject mitotic cells first, and then immediately thereafter treat them with nocodazole. We found that cells injected with wild-type XCL100 protein during prometaphase or metaphase gradually began to exit mitosis ∼45 min to 1 h after nocodazole treatment, without re-forming spindles or carrying out sister chromatid segregation, karyokinesis, or cytokinesis (Table [I](#TI){ref-type="table"}). Initially, the chromosomes became clustered and then decondensed, and finally the nuclear envelope reformed and nucleoli appeared (Fig. [5](#F5){ref-type="fig"}). The resulting cells resembled typical, flat interphase cells, except that the cells and their nuclei were unusually large (Fig. [5](#F5){ref-type="fig"}). When cells were injected during prophase (before nuclear envelope breakdown) and then treated with nocodazole, they did not exit mitosis.

We carried out a variety of experiments to assess the specificity of the effects of XCL100 microinjection on metaphase arrest. First, the possibility that cells escaped the checkpoint control because of microinjection trauma was assessed by injection of buffer alone. All cells (10/10) injected with buffer behaved the same as noninjected ones: they remained mitotically arrested for at least 4 h after nocodazole treatment, indicating no detectable effect of microinjection per se (Table [I](#TI){ref-type="table"}).

Next, we determined whether the effect of XCL100 on mitotic arrest was dependent on its phosphatase activity. We injected cells with purified recombinant XCL100 C260S protein, the inactive mutant form, at a needle concentration of 1.5 μM. All cells (17/17) injected with XCL100 C260S protein maintained normal mitotic arrest for at least 4 h when treated with nocodazole (Fig. [5](#F5){ref-type="fig"}; Table [I](#TI){ref-type="table"}). This result indicates that the effect of XCL100 on the spindle assembly checkpoint is dependent on its phosphatase activity.

We also set out to determine whether any active Erk1 or Erk2 was present in nocodazole-arrested XTC cells, as should be the case if the effects of XCL100 were due to inactivation of one of these MAP kinases. We prepared lysates from asynchronous XTC cells, from cells incubated for various lengths of time (15 min through 7 h) with nocodazole, and from cells shaken off of a plate of cells that had been treated with nocodazole for 16 h. We subjected these samples to immunoblotting with an antiserum that recognizes active Erk1 and Erk2 (Promega). Small amounts of active Erk2 were detected in all of the nocodazoletreated samples (∼⩽10% of the total Erk2), and no active Erk1 was detected (data not shown). The presence of some active Erk2 in the nocodazole-treated cells is compatible with the hypothesis that XCL100\'s effects on mitotic arrest were due to inactivation of Erk2. However, similar amounts of active Erk2 were detected in untreated, asynchronous cells (data not shown). In contrast, [@B48] found marked differences in the activity of Erk2 in interphase vs mitotically arrested cycling extracts. Thus, mitotic activation of MAP kinase is either more subtle or more difficult to detect in intact XTC cells than it is in extracts.

XCL100 C260S can bind avidly to phosphorylated Erk2, and therefore could potentially interfere with MAP kinase function by preventing MAP kinase from interacting with its substrates ([@B67]). However, it seems unlikely that this type of inhibition would occur to any significant extent at the concentration of XCL100 C260S we have injected in our studies. [@B67] found that expression of the C258S mutant of mouse Mkp-1 (the mouse homolog of XCL100) in COS cells at levels substantially greater than the levels of Erk2 resulted in the coprecipitation of ∼30% of the cells\' Erk2 with the Mkp-1 C258S. However, in our case, the concentration of microinjected XCL100 C260S was ∼20-fold lower than the concentration of Erk2 (75 nM vs 1--2 μM). Thus, we would expect our injected phosphatases to be able to inhibit MAP kinase function only by dephosphorylation, not by sequestration. This is consistent with our finding here that XCL100 interfered with mitotic arrest, and XCL100 C260S did not. Similarly, we have found that microinjection of wild-type XCL100 mRNA inhibits progesterone-induced oocyte maturation, whereas XCL100 C260S does not (Sohaskey, M.L., unpublished data).

The Effect of XCL100 on Mitotic Arrest Is Due to Its Effects on p42 or p44 MAP Kinase
-------------------------------------------------------------------------------------

We set out to determine whether the effect of XCL100 on mitotic arrest was due to its effect on p42/p44 MAP kinase, p38 Hog1, or some other as yet unidentified target. Our approach was to coinject XCL100 with a constitutively active MAP kinase kinase (MKK-1\*) ([@B46]). MKK-1\* has no direct effect on XCL100 but exerts an effect on MAP kinase that is opposite to the effect of XCL100: it phosphorylates the same residues that XCL100 dephosphorylates. MKK-1 is a highly specific protein kinase. It does not phosphorylate p38 Hog1, and biochemical and genetic studies have thus far uncovered no evidence for the existence of substrates of MKK-1 other than p42 and p44 MAP kinase ([@B3]; [@B10]; [@B45]; [@B65]). Thus, if MKK-1\* were found to antagonize the effect of XCL100 on mitotic arrest, this would be strong evidence that XCL100\'s effects on mitotic arrest were due to its effect on p42 or p44 MAP kinase.

We coinjected XCL100 (needle concentration 1.5 μM) with MKK-1\* (needle concentration 5 μM; based on in vitro assays \[Fig. [4](#F4){ref-type="fig"} *C*\], this concentration should substantially counteract the effects of the coinjected XCL100) into XTC cells at metaphase or prometaphase, and then immediately treated the cells with nocodazole. We found that the injected cells (8/8) did not exit mitosis; they remained blocked at pseudo-prometaphase stage with scattered chromosomes for at least 4 h (Fig. [5](#F5){ref-type="fig"}; Table [I](#TI){ref-type="table"}). These findings indicate that MKK-1\* inhibited or overcame the effects of XCL100 on mitotic arrest. This supports the hypothesis that the effects of XCL100 on mitotic arrest are due to its effects on p42 or p44 MAP kinase, rather than to some other possible target.

Finally, we assessed whether MAP kinase activation was sufficient to bring about metaphase arrest. We addressed this question by injecting MKK-1\* alone (needle concentration 10 μM) into mitotic XTC cells. We found that microinjection of this protein did not bring about a mitotic arrest. This finding suggests either that MAP kinase activation is not sufficient for mitotic arrest, or that we were unable to achieve a high enough level of MAP kinase activation to bring about mitotic arrest.

Discussion
==========

Spindle Localization of MAP Kinase Provides a Clue to Its Role in Mitosis
-------------------------------------------------------------------------

Several workers have previously examined the localization of the Erk1 and Erk2 MAP kinases in interphase tissueculture cells. Erk1/Erk2 have been reported to be distributed in a diffuse ([@B8]; [@B14]; [@B41]; [@B69]) or diffusely speckled ([@B4]) pattern in a variety of quiescent cells and to translocate to the nucleus when the cells are treated with mitogens. However, recent evidence indicates that, in at least some cell types, MAP kinase may concentrate on or around microtubules ([@B49]; [@B62]). Here we found that, in interphase XTC cells, the Erk1/Erk2 distribution is diffuse; we saw no examples of microtubule-like staining in these cells.

When XTC cells entered M phase, some MAP kinase immunofluorescence was found to concentrate in the spindle. This could represent MAP kinase translocating to the spindle or, possibly, microtubule-associated MAP kinase undergoing some change in association that made it more accessible to antibody staining. MAP kinase spindle staining was strongest during metaphase and decreased by anaphase, and MAP kinase staining was absent from the cytokinesis midbody.

In some ways, the changes in MAP kinase localization during mitotic M phase reported here are similar to those reported by [@B70] and [@B6] for meiotic M phase. [@B70] found MAP kinase to concentrate at the spindle poles in mouse oocytes in meiotic M phase and to become more diffuse in anaphase. This is similar to our finding, except that we found MAP kinase to be present throughout the spindle rather than just at the spindle poles. [@B6] found MAP kinase to concentrate in the miniasters that form near the chromosomes in mouse oocytes in early meiotic M phase, again reminiscent of the spindle localization we found.

The presence of MAP kinase in the mitotic spindle puts it in a position either to monitor the status of the spindle, or to regulate spindle-associated proteins, or both. It also places MAP kinase in the proximity of key cell cycle regulators. In particular, cyclin B1/Cdc2 complexes appear to be largely spindle associated during M phase, and a fraction of the cyclin B2 is as well ([@B34]; [@B56], [@B57], [@B58]; [@B59]; [@B61]).

Microinjection of MAP Kinase Phosphatase Has No Apparent Effect on Mitotic Progression
--------------------------------------------------------------------------------------

Erk2 becomes activated concomitantly with Cdc2 during oocyte maturation, and manipulations that inhibit the activation of MAP kinase ([@B18]; [@B30]; [@B39]) or its upstream activators ([@B13]; [@B66]) inhibit Cdc2 activation. In addition, microinjection of oocytes with constitutively active MAP kinase ([@B22]), constitutively active Mek-1 (a MAP kinase kinase; [@B32]), constitutively active Raf-1 (a MAP kinase kinase kinase; [@B53]), or Mos (a MAP kinase kinase kinase; [@B73]) brings about Cdc2 activation. These findings place Erk2 upstream of Cdc2 during meiosis and raise the possibility that MAP kinases may be important for Cdc2 activation at the onset of mitosis as well. It has also been shown that purified Erk2 can cause centrosomenucleated microtubules to change from interphase-like stability to M-phase--like instability ([@B17]). Thus, MAP kinase could be involved in the changes in microtubule dynamics that occur during both meiosis and mitosis.

However, there is conflicting evidence on whether Erk1 or Erk2 is activated during mitotic M phase ([@B9]; [@B27]; [@B68]), and the question of whether Erk1 or Erk2 function is required for entry into or progression through mitotic M phase has not been previously addressed. In the present study we detected small amounts of active Erk2 in M-phase cells but found no indication that MAP kinase function was important for normal mitotic progression; microinjection of the MAP kinase phosphatase XCL100 had no obvious effect. We cannot rule out the possibility that microinjection of a higher concentration of XCL100, or microinjection of XCL100 before prophase, might alter mitotic progression.

MAP Kinase Function Is Required for the Spindle Assembly Checkpoint
-------------------------------------------------------------------

Previous work demonstrated that *Xenopus* egg extracts supplemented with nuclei arrest in a mitotic state when treated with nocodazole, and that addition of mouse MAP kinase phosphatase (Mkp-1) to these extracts releases them from mitotic arrest ([@B48]). These findings suggest a role for MAP kinase in the spindle assembly checkpoint, provided the reconstituted extract system faithfully recapitulates the checkpoint controls found in intact cells.

Here we present strong evidence that MAP kinase function is required for the spindle assembly checkpoint in intact XTC cells. Microinjection of active XCL100 during prometaphase or metaphase (but not prophase) abrogates the normal spindle assembly checkpoint, whereas microinjection of saline or an engineered inactive XCL100 mutant protein does not. Coinjection of MKK-1\*, a constitutively active MAP kinase kinase, abolishes the effect of XCL100 on the spindle assembly checkpoint. This finding argues that the relevant target of XCL100 is p42 or p44 MAP kinase, rather than p38 Hog1 or some adventitious target. It is also possible that the relevant target is some as yet unidentified protein that can be regulated by both XCL100 and MKK-1\*.

Previous work has also shown that MAP kinase function is required for the metaphase arrest that occurs naturally during the maturation of frog oocytes ([@B21]; [@B38]; [@B48]); i.e., MAP kinase is an essential mediator of "cytostatic factor" function. Taken together with Minshull et al.\'s studies of the spindle assembly checkpoint in extracts and the present studies of the spindle assembly checkpoint in intact cells, it appears that M-phase arrest in a variety of biological contexts depends upon MAP kinase function. It is therefore possible that studies of any one of these systems might yield insights into all of them.

At present, the mechanism through which MAP kinase mediates the spindle assembly checkpoint is unknown. The possibilities can be organized into three general classes of mechanism. (*a*) MAP kinase could regulate the machinery that detects spindle misassembly or chromosome misalignment. (*b*) MAP kinase could regulate the cyclin destruction machinery. For example, MAP kinase could regulate whatever specific ubiquitin-conjugating enzymes are responsible for ubiquitinating cyclins B1 and B2. (*c*) MAP kinase could convert cyclins B1 and B2 to phosphorylated, nondestructible forms. This possibility is supported by the observation that cyclin B1 is a good substrate for p42 MAP kinase ([@B33]). Cyclin B2 is not a good substrate for Erks 1 or 2, but Minshull et al. have demonstrated the existence of one or more cyclin B2 kinase activities that appear to be MAP kinase dependent ([@B48]).

Likewise, it is not understood what lies upstream of MAP kinase in the spindle assembly checkpoint. It is unclear whether the checkpoint makes use of known MAP kinase kinases (MKK-1/Mek-1, MKK-2/Mek-2) and known MAP kinase kinase kinases (Mos, Raf-1, A-Raf, and B-Raf), or whether there are unknown MAP kinase cascade components used specifically for this function. Our hope is that through a combination of in vivo analysis, like that described here, and examination of in vitro systems, as described previously, it may be possible to delineate the signaling pathways used in the spindle assembly checkpoint in detail.
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![Purification and characterization of the GST--XCL100 fusion protein. (*A*) Purification of bacterially expressed GST-XCL100. Full-length GST-XCL100 migrates at ∼67 kD. The prominent band at ∼27 kD in the glutathione agarose purified sample is GST. After Mono-Q purification, full-length GST-XCL100 was the main band detectable by Coomassie staining, and a single band was detectable by XCL100 immunoblotting. (*B*) Activity of GST-XCL100. This panel shows a MAP kinase immunoblot of recombinant nonphosphorylated rat Erk2 (*MK*), and phosphorylated rat Erk2 (*MK-P*) incubated with no phosphatase, with GST-XCL100, or with the inactive GST-XCL100 C260S mutant. (*C*) In vitro titration of GST-XCL100 activity. Various concentrations of GST-XCL100 were mixed with 250 nM MKK-1\* and 1 μM *Xenopus* Erk2, and the system was allowed to reach steady state. MAP kinase activity was determined by a myelin basic protein phosphorylation assay.](JCB.wang4){#F4}

![The specificity of antibody X15. Immunoblots of lysates from XTC cells (lane *1*), G2-phase oocytes (lane *2*), and M-phase oocytes (lane *3*) were probed with X15. XTC cells exhibited two bands: a lower band that comigrated with nonphosphorylated Erk2, and an upper band that comigrated with both Erk1 and phosphorylated Erk2. The upper band was identified as Erk1, rather than phosphorylated Erk2, based on its cross-reactivities with other Erk1 and Erk2 antisera, and on the fact that it did not shift to a lower apparent molecular weight when lysates were treated with XCL100 (not shown).](JCB.wang1){#F1}

![Immunolocalization of MAP kinase at different mitotic stages. XTC cells were fixed, permeabilized, and subjected to triple label staining with DAPI, X15, and a β-tubulin antibody (*A--F*), or with DAPI, X15 preimmune serum, and the tubulin antibody (*G*).](JCB.wang2){#F2}

![Single label immunolocalization of MAP kinase. XTC cells were fixed, permeabilized, stained with DAPI (not shown) and X15 or X15 plus blocking peptide (35 μM), and examined by fluorescence and phase microscopy. The cell shown is in metaphase.](JCB.wang3){#F3}

###### 

The Effect of Inhibiting MAP Kinase Activation on the Spindle Assembly Checkpoint: Summary of Microinjection Data

  Treatment                                                     Outcome                                                                                   
  ---------------------------------------------------------- -- ----------------------------------------- -- ----------------------------------------- -- -----------------------------------------
  Nocodazole plus buffer injection                              10/10                                         0/10                                         0/10
  XCL100 injection                                               0/20                                        20/20                                         0/20
  Nocodazole plus XCL100[‡](#TFI-152){ref-type="table-fn"}       0/15[‡](#TFI-152){ref-type="table-fn"}       0/15[‡](#TFI-152){ref-type="table-fn"}      15/15[‡](#TFI-152){ref-type="table-fn"}
  Nocodazole plus XCL100 C260S                                  17/17                                         0/17                                         0/17
  MKK-1\* injection                                              0/19                                        19/19                                         0/19
  Nocodazole plus XCL100 plus MKK-1\*                            8/8                                          0/8                                          0/8

 The data tabulated here are taken from four independent microinjection experiments using four separate preparations of XCL100. Three other preparations of XCL100 showed no effect (cells remained arrested in mitosis for 4 h after nocodazole treatment) when microinjected into a total of about a dozen mitotic cells.  

![Effects of perturbing MAP kinase function on the spindle assembly checkpoint. Mitotic cells were microinjected with the inactive XCL100 C260S mutant (*left*), wild-type XCL100 (*middle*), or XCL100 plus MKK-1\* (*right*), and then treated with nocodazole. The morphological consequences were assessed by time-lapse video microscopy. Four images are shown from each video series. Numbers in each panel denote the time (in h and min) after nocodazole treatment.](JCB.wang5){#F5}
